Two-Stage Microchip Drug Release for Fast and Sustained Dosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing drug delivery devices struggle to maintain drug plasma levels within a selected therapeutic range and avoid undesirable lag times in reaching effective levels, whether through bolus or extended-release mechanisms.
Innovation Solution
A microchip-based drug delivery device with a two-stage release system, utilizing electrothermal ablation to open reservoir caps and a drug-permeable membrane, allowing drug diffusion through a depot space for controlled release, independent of bioerodible matrices.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If bolus delivery is used, then initial drug concentration is high, but drug levels rapidly decrease below therapeutic range
Solution Approach 1:
The device segments the drug delivery process into two distinct stages: a first stage with high-concentration bolus delivery to rapidly achieve therapeutic levels, and a second stage with lower-concentration extended release to maintain therapeutic levels. This segmentation allows the device to overcome the limitation of conventional single-stage delivery systems that must choose between rapid delivery (bolus) or sustained delivery (extended-release), enabling both objectives to be achieved sequentially.
2Duration of action of moving object
If extended-release delivery is used, then drug levels remain in therapeutic range longer, but initial lag time to reach effective levels is undesirably long
Solution Approach 1:
The device performs preliminary action by delivering a high-concentration bolus dose in the first stage to rapidly achieve therapeutic drug levels, eliminating the lag time problem. This initial aggressive delivery ensures immediate therapeutic effect, after which the system transitions to the second stage for sustained maintenance of therapeutic levels.
3Duration of action of moving object
If passive diffusion from matrix material is used, then extended release is achieved, but device complexity increases and manufacturing becomes more difficult
Solution Approach 1:
The invention extracts and eliminates the complex bioerodible matrix material from the device architecture. Instead of relying on passive diffusion through complex matrix structures, the device uses a simpler reservoir-based system with controlled release through apertures and membranes, significantly reducing manufacturing complexity while maintaining extended-release functionality.
4Duration of action of moving object
If conventional extended-release devices are used, then drug release is continuous, but inability to provide discrete dosing reduces adaptability
Solution Approach 1:
The device incorporates dynamic control capabilities that allow it to adapt between different dosing modes. The system can be programmed to provide either continuous release or discrete dosing schedules based on therapeutic requirements, enabling clinicians to optimize dosing strategies for different patient needs and drug characteristics.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The device maintains systemic drug concentrations within a therapeutic window for extended periods, providing nearly linear drug release and reducing lag times by combining discrete and continuous dosing.
Implementation Method 1
one or more corresponding reservoir caps configured to be electrically activated to unclose the one or more drug release apertures
Implementation Method 2
release the drug by diffusion through the drug-permeable membrane and into the aqueous environment
Data Source
AI summary
Drug delivery devices and methods of controlled drug delivery to a patient are provided. The drug delivery device may include one or two microchip elements, each of which has a body portion with one or more drug release apertures in fluid communication with at least one containment reservoir. The drug release apertures are closed off by one or more reservoir caps which can be electrically activated to open the drug release apertures. The drug delivery device also includes (i) a drug formulation disposed in the at least one containment reservoir, and (ii) at least one drug-permeable membrane. In some cases, an outer housing is spaced a distance from an exterior wall of the body portion of the microchip element, the outer housing includes the at least one drug-permeable membrane, and a depot space is defined between the drug-permeable membrane and the exterior wall of the body portion of the microchip element.